Authorized purpose: Better Diagnostics Caries Assist is a concurrent-read computer-aided detection device that identifies and localizes carious lesions on bitewing and periapical radiographs of adults age 18 and older for review by licensed dentists; it does not replace complete dental review or clinical judgment.
Clinical role
Dental image viewing, measurement, second-reader, detection, segmentation, or treatment-planning support.
Images and patients
X-ray/Radiography · Dental permanent dentition and carious lesions
Key limitation
Keep in mind: The exact dental view, patient age, dentition, image quality, and concurrent clinical evaluation limits applicability; outputs do not replace professional judgment.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Better Diagnostics Caries Assist is a concurrent-read computer-aided detection device that identifies and localizes carious lesions on bitewing and periapical radiographs of adults age 18 and older for review by licensed dentists; it does not replace complete dental review or clinical judgment.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Dental permanent dentition and carious lesions Input: Supported dental radiographs, CBCT, DICOM studies, or imported dental-image objects described in the exact submission.
Who uses it?Intended users: Licensed dentists, dental radiologists, and other trained dental healthcare professionals.
What does the software produce?Output: Dental image marks, contours, measurements, three-dimensional views, or planning information for professional review.
What is its most important limitation?Key limitation: The exact dental view, patient age, dentition, image quality, and concurrent clinical evaluation limits applicability; outputs do not replace professional judgment.
Clinical takeaway. Clinical role: Better Diagnostics Caries Assist is a concurrent-read computer-aided detection device that identifies and localizes carious lesions on bitewing and periapical radiographs of adults age 18 and older for review by licensed dentists; it does not replace complete dental review or clinical judgment.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a standalone study on 614 BW and 684 IOPA images (15,687 and 9,253 surfaces), with ground truth by consensus of two out of three licensed dentists. Primary surface-level results: BW sensitivity 89.2% (adjusted 95% CI [86.15%, 92.13%]) and specificity 99.5% (CI [99.32%, 99.57%]); IOPA sensitivity 88.2% (CI [85.27%, 90.78%]) and specificity 99.1%. A reader study reported aided AUCs of 0.848 (BW) and 0.845 (IOPA) versus unaided 0.806 and 0.807. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Better Diagnostics Caries Assist is a concurrent-read computer-aided detection device that identifies and localizes carious lesions on bitewing and periapical radiographs of adults age 18 and older for review by licensed dentists; it does not replace complete dental review or clinical judgment.
The exact dental view, patient age, dentition, image quality, and concurrent clinical evaluation limits applicability; outputs do not replace professional judgment.
The exact FDA document reports a standalone study on 614 BW and 684 IOPA images (15,687 and 9,253 surfaces), with ground truth by consensus of two out of three licensed dentists. Primary surface-level results: BW sensitivity 89.2% (adjusted 95% CI [86.15%, 92.13%]) and specificity 99.5% (CI [99.32%, 99.57%]); IOPA sensitivity 88.2% (CI [85.27%, 90.78%]) and specificity 99.1%. A reader study reported aided AUCs of 0.848 (BW) and 0.845 (IOPA) versus unaided 0.806 and 0.807. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "For BW images, out of 614 images, 310 indicated the presence of cavities. Among the 15,687 surfaces examined within these images" … "Similarly, for IOPA images, of the 684 images analyzed, 367 showed indications of cavities. Out of 9,253 surfaces reviewed". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports a standalone study on 614 BW and 684 IOPA images (15,687 and 9,253 surfaces), with ground truth by consensus of two out of three licensed dentists. Primary surface-level results: BW sensitivity 89.2% (adjusted 95% CI [86.15%, 92.13%]) and specificity 99.5% (CI [99.32%, 99.57%]); IOPA sensitivity 88.2% (CI [85.27%, 90.78%]) and specificity 99.1%. A reader study reported aided AUCs of 0.848 (BW) and 0.845 (IOPA) versus unaided 0.806 and 0.807. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "For BW images, out of 614 images, 310 indicated the presence of cavities. Among the 15,687 surfaces examined within these images" … "Similarly, for IOPA images, of the 684 images analyzed, 367 showed indications of cavities. Out of 9,253 surfaces reviewed". Read from the exact FDA decision document on 2026-11-14.
Standalone surface-level sensitivity for caries on BW images: 89.2% (adjusted 95% CI 86.15%-92.13%); on IOPA images: 88.2% (CI 85.27%-90.78%).
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "The primary analysis in the standalone study was conducted at the surface level" … "BW Surface Level: The BDCA achieved a sensitivity of 89.2% with an adjusted 95% CI of [86.15%, 92.13%], and a specificity of 99.5% with a CI of [99.32%, 99.57%].". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
Standalone surface-level specificity for caries on BW images: 99.5% (CI 99.32%-99.57%); on IOPA images: 99.1% (CI 98.88%-99.31%).
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "BW Surface Level: The BDCA achieved a sensitivity of 89.2% with an adjusted 95% CI of [86.15%, 92.13%], and a specificity of 99.5% with a CI of [99.32%, 99.57%]." … "IOPA Surface Level: The device reached a sensitivity of 88.2% with a CI of [85.27%, 90.78%] and a specificity of 99.1%". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K241725 FDA evidence package for Better Diagnostics Caries Assist (BDCA) Version 1.0
DesignFDA 510(k) decision evidence package reviewed for exact submission identity and labeled scope
PopulationLabeled population and configuration described in the K241725 FDA decision material
Scopeexact submission
Tested versionBetter Diagnostics Caries Assist configuration described in K241725
IndependenceSponsor or vendor study
K241725
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K241725 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported dental radiographs, CBCT, DICOM studies, or imported dental-image objects described in the exact submission.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes APIs that receive images from the Dental PMS and pass annotations and coordinates to a presentation layer hosted by the Dental PMS; the system processes PNG, BMP and JPG images. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "BDCA v1.0 APIs connect the Dental PMS with the business layer. API receives images input from Dental PMS and passes it to the business layer." … "It also receives annotations and co-ordinates from the business layer and passes it to the presentation layer hosted by Dental PMS.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes BDCA v1.0 computer vision models hosted on a cloud computing platform, with AI-marked annotations shown in a web-based user interface. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "These models are hosted on a cloud computing platform and are responsible for image processing." … "a web-based interface (user interface) that allows users to view AI marked annotations.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Dental image marks, contours, measurements, three-dimensional views, or planning information for professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Dental image marks, contours, measurements, three-dimensional views, or planning information for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes BDCA v1.0 computer vision models hosted on a cloud computing platform, with AI-marked annotations shown in a web-based user interface. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "These models are hosted on a cloud computing platform and are responsible for image processing." … "a web-based interface (user interface) that allows users to view AI marked annotations.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes APIs that receive images from the Dental PMS and pass annotations and coordinates to a presentation layer hosted by the Dental PMS; the system processes PNG, BMP and JPG images. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "BDCA v1.0 APIs connect the Dental PMS with the business layer. API receives images input from Dental PMS and passes it to the business layer." … "It also receives annotations and co-ordinates from the business layer and passes it to the presentation layer hosted by Dental PMS.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Only licensed dentists, dental radiologists, and other trained dental healthcare professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Exact public integration details remain incomplete; establish and test the supported input, output, identity, routing, archive, report, and downtime contract locally.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the exact labeled population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The exact dental view, patient age, dentition, image quality, and concurrent clinical evaluation limits applicability; outputs do not replace professional judgment.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in reviewed public material; productivity or value claims require local evidence.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. No exact native-submission recall record was found in the checked snapshot; this does not exclude other product-family or later signals.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Installation timeline: Not yet reviewed
Monitoring: Not publicly available - checked 2026-09-04 - Exact FDA submission
The exact FDA decision and checked recall snapshot do not establish a complete local postmarket monitoring protocol. Track version, population, anatomy, protocol, input quality, edits, failures, repeats, downstream effects, downtime, incidents, recalls, and updates locally.
Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.
Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Authorized purpose: Analyze frontal chest and abdominal X-ray images to detect and localize a nasally or orally inserted enteric tube, its tip and side port if present, and the diaphragm and airways for radiologist review.
Modality
X-ray/Radiography
Anatomy
Chest/lung and abdomen/stomach; enteric tube, tube tip and side port, diaphragm, and airways including carina and left/right bronchi
Authorized purpose: qXR-Detect is an adult chest-radiograph concurrent reading aid that identifies, highlights and categorizes suspicious regions of interest across lung, pleura, mediastinum/hila/heart, bone, hardware and other categories; trained clinicians remain responsible for primary interpretation.
Modality
X-ray/Radiography
Anatomy
Chest/Lung; pleura, mediastinum/hila/heart, bone, hardware and other chest-radiograph regions
Authorized purpose: Provides automated concurrent-read detection and segmentation of caries on bitewing radiographs in patients 18 and older, adding information for the dentist while requiring complete dentist review and judgment.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.